JPS63115818A - Local composition for improving or extinguishing pain after operation - Google Patents
Local composition for improving or extinguishing pain after operationInfo
- Publication number
- JPS63115818A JPS63115818A JP62210365A JP21036587A JPS63115818A JP S63115818 A JPS63115818 A JP S63115818A JP 62210365 A JP62210365 A JP 62210365A JP 21036587 A JP21036587 A JP 21036587A JP S63115818 A JPS63115818 A JP S63115818A
- Authority
- JP
- Japan
- Prior art keywords
- cortisone
- pain
- wound
- preparation
- extinguishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 7
- 208000002193 Pain Diseases 0.000 title description 9
- 230000036407 pain Effects 0.000 title description 9
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 38
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 38
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 38
- 229960004544 cortisone Drugs 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 24
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 208000004550 Postoperative Pain Diseases 0.000 claims description 6
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 claims description 5
- 229940106885 marcaine Drugs 0.000 claims description 5
- 229940035674 anesthetics Drugs 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 229940072358 xylocaine Drugs 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229960004648 betamethasone acetate Drugs 0.000 claims 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 230000002980 postoperative effect Effects 0.000 description 13
- 239000003589 local anesthetic agent Substances 0.000 description 10
- 208000002847 Surgical Wound Diseases 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010006585 Bunion Diseases 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000001255 hallux Anatomy 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010066962 Procedural nausea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 229940087110 celestone Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Abstract] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は手術から回復する患者の体ｐａする痛みを改善
又は消滅させる方法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for improving or eliminating paralysis pain in a patient recovering from surgery.
従来は１例えば、嗜眠状態又は悪心のような有害なｎ１
作用をも生じることなく術後痛［ｐｏｓｔｏｐｅｒａｔ
ｉｖｅ ｐａｉｎ］を改善又は消滅させるのに有効な鎮
痛剤は開示されていない。Previously 1 harmful n1 such as drowsiness or nausea
Post-operative pain without any effect
No analgesic agent has been disclosed that is effective in ameliorating or eliminating ive pain.
本発明の目的には、このような有害な副作用をも生じる
ことなく術後痛を軽減する処置を提供することがある１
本発明のこの目的及び他の目的は。An object of the present invention is to provide a treatment that reduces postoperative pain without causing such harmful side effects.
This and other objects of the invention.
以下の説明によって一層理解されよう。This will be better understood with the following explanation.
−本発明によると、コルチゾン調剤の術後傷領域への局
所適用は術後痛の軽減又は消滅に有用となる９本発明方
法により２手術の完了後、術１８傷の新しい手術面を一
回該コルチゾン調剤に浸１．少量の物質を傷面に常法０
例えばアトマイザを用いる直接噴霧又は注射器又は針を
用いる洗浄によって適用する。コルチゾン調剤は適用後
食塩水で洗出されない、（Ｉは普通に塞ぐ、過剰のコル
チゾン調剤は傷から普通に流出する０通常の治シが起る
。- According to the invention, local application of a cortisone preparation to the postoperative wound area is useful in reducing or eliminating postoperative pain. Soaking in the cortisone preparation 1. Apply a small amount of substance to the wound surface using a conventional method.
For example, it is applied by direct spraying using an atomizer or by irrigation using a syringe or needle. Cortisone preparations are not flushed out with saline after application (I normally occlude, excess cortisone preparation drains normally from the wound, normal healing occurs).
さらに１本発明によると、術後傷の新手沿面はコルチゾ
ンと局所麻酔薬又は他の痛解ｒＩｉ薬とで処置すること
ができる。Further in accordance with the present invention, the new hand side of the post-operative wound can be treated with cortisone and local anesthetics or other analgesic drugs.
局所麻酔薬、好ましくはマルカイン
（Ｍａｒｃａｉｎｅ ） 、キシロカイン（Ｘ ｙｌｏ
ｃａｉｎｅ） 。Local anesthetics, preferably Marcaine, Xylocaine
caine).
リドカイン（ｌ １ｄＯｃａｉｎ６１） 、ノバカイン
（Ｎ ０ＶａＣａｉｎｅ）等の長く作用する麻酔薬をコ
ルチゾンと共に又は別個に手術後の最初の数時間の痛み
を即時消滅させるために適用することが患者にとて役立
つことが見出だされた。この時間はコルチゾンの作用が
最も弱い期間だからである。It may be helpful for patients to apply long-acting anesthetics such as lidocaine (11dOcaine61), Novacaine (N0VaCaine) together with cortisone or separately to immediately eliminate pain in the first few hours after surgery. discovered. This is because this is the period during which the effect of cortisone is at its weakest.
術後但領域へのコルチゾン調剤の局所適用はめざましい
効果がある。術後痛は著しく減少するか又は消滅する０
両側手術の場合、比較のために。Local application of cortisone preparations to the post-operative area has a remarkable effect. Postoperative pain is significantly reduced or disappears0
In case of bilateral surgery, for comparison.
一方をコルチゾン調剤で処置し他方を未処置のままで放
置すると、患者は未処置側では痛みのある術後回復に耐
えるが処置した側では意味のある痛みを体験しない。If one is treated with a cortisone preparation and the other is left untreated, the patient will endure a painful postoperative recovery on the untreated side, but will not experience any meaningful pain on the treated side.
容易に入手できる局所適用可能な任意のコルチゾン調剤
がこの目的のために使用できる。セレストン懸濁体［Ｓ
ｃｈｅｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ。Any readily available topically applicable cortisone preparation can be used for this purpose. Celestone suspension [S
chering Corporation.
Ｋ ｅｎｉｌｗｏｒｔｈ、Ｎ 、 Ｊ 、から Ｃｅ＋
ｅｓｔｏｎｅｓ ０１ｕＳｐａｎとして販売されている
コが好ましいが。Kenilworth, N, J, to Ce+
The one sold as estones 01uSpan is preferred.
噴霧できるか又は局所適用に適した他のコルチゾン調剤
も使用できる。セレストン懸濁体は、殺菌ベーターメタ
シン［ｂｅｔａ−ｍｅｔｈａｓｏｎｅ ］ナトリウム
フォスフェート及びベーターメタシン アセテートＵＳ
Ｐの懸濁体商標である。Other cortisone preparations that are nebulizable or suitable for topical application may also be used. Celeston suspension is made from sterile beta-methasone sodium.
Phosphate and Betamethacin Acetate US
It is a suspension trademark of P.
手術傷に適用するコルチゾンの旦は変ることができ、但
の激しさ及び範囲のような因子に左右される。用いるコ
ルチゾンの有効量は特定状況に応じて容易に確めること
ができる。The amount of cortisone applied to surgical wounds can vary and depends on factors such as severity and extent. The effective amount of cortisone to use can be readily determined depending on the particular situation.
コルチゾンは抗炎症剤として作用し１１Ｊ＋！腫脹を減
少し、それによって周囲の神経の上の痛圧を減少させる
。それに加えて、コルチゾンは神経の厳しい末端に直接
作用する４手術傷に局所的に適用した場合のコルチゾン
の作用機構をさらに定めるために研究が続けられている
。Cortisone acts as an anti-inflammatory agent and has 11J+! Reduces swelling and thereby reduces pain pressure on surrounding nerves. In addition, research continues to further define the mechanism of action of cortisone when applied topically to surgical wounds, where cortisone acts directly on the tough endings of nerves.
手術傷に適用する局所麻酔薬又は他の痛解放薬の瓜は変
ることができ、傷の激しさ及び範囲のような因子に左右
される。用いる麻酔薬の有効量は特定状況に対して容易
にＩ認できる。The amount of local anesthetic or other pain relief agent applied to a surgical wound can vary and depends on factors such as the severity and extent of the wound. The effective amount of anesthetic to be used can be readily determined for the particular situation.
麻酔薬は手術傷にコルチゾンと共に又は別個に状況に応
じて適用することができる。容易に入手できる局所適用
可能な任意の局所麻酔調剤がこの目的のために使用でき
る。用いることができる麻酔薬の代表例には、マルカイ
ン、キシロカイン。Anesthetics can optionally be applied to the surgical wound together with cortisone or separately. Any readily available locally applicable local anesthetic preparation can be used for this purpose. Representative examples of anesthetics that can be used include marcaine and xylocaine.
リドカイン、ノバカイン等がある。麻酔薬は手術傷に任
意の方法２例えば噴霧、洗浄、散布又は利用できる適当
なりｖＡで適用できる。These include lidocaine and novacaine. The anesthetic can be applied to the surgical wound in any manner 2, such as spraying, washing, dispersing, or whatever vA is available.
本発明を次の例で説明する。これらの例は説明のために
のみあげるもので３本発明を限定するためのもめではな
い。The invention is illustrated by the following example. These examples are given for illustrative purposes only and are not intended to limit the invention.
例 １
両側ケラーバニオン切除
［）（ｅｌｌｅｒ １３ｕｎｉｏｎｅｃｔｏＩＩｌｙ
］足の母指の第−ＭＰｌｉ１節の内側面の上の軟組織を
切除する。切除は軟組織を通り母指の第−開面まで続け
る。母指の近位指部骨を第一中足骨の遠位面の内側面上
のバニオンと共に除く、新骨質域を切除軟組織と共に露
出させる。Example 1 Bilateral Keller bunion excision [) (eller 13 unionecto IIly
] Excise the soft tissue above the medial aspect of the -MPli1 segment of the big toe. The resection continues through the soft tissue to the second incision of the thumb. The proximal phalanx of the big toe is removed along with the bunion on the medial aspect of the distal surface of the first metatarsal, and the new bony area is exposed along with the resected soft tissue.
コルチゾン調剤１例えばセレストン懸濁体を傷の新手桁
面に７トマイザを用いる直接噴霧か又は注射器及び針を
用いる洗浄によって局所的に適用する。噴霧の場合には
、１′ｉ手術組織に１ｃｃのコルチゾン調剤を適用し、
洗浄の場合には、１．５〜２ｃｃを適用する。物質は一
回のみ用いる。コルチゾン調剤は適用後食塩水で洗出さ
れない、過剰のコルチゾン調剤は傷から重力で流出する
０通常の治癒が起る。Cortisone preparation 1, such as Celeston suspension, is applied topically to the fresh surface of the wound by direct spraying with a 7tomizer or irrigation with a syringe and needle. For nebulization, apply 1 cc of cortisone preparation to 1'i surgical tissue;
For cleaning, apply 1.5-2 cc. Substances are used only once. Cortisone preparations are not washed out with saline after application; excess cortisone preparation drains out of the wound by gravity; normal healing occurs.
患者はコルチゾンのみを用いると回復室で一般に若干の
不快を示す、しかしながら、一般麻酔からの回復に続（
ときは９手術域の最小の不快を体験する０足の上に圧迫
包帯を用いると、患者は室から直ちに歩行等が可能であ
る。Patients generally exhibit some discomfort in the recovery room with cortisone alone; however, following recovery from general anesthesia (
When 9 patients experience minimal discomfort in the surgical area and 0 compression bandages are used on the legs, the patient is able to ambulate immediately from the room.
比較の目的で、一方の足をコルチゾン調剤で処置し、他
方の足を未処置のままにすると、ｆＱ者の反応は劇的で
ある。患者は未処置の足についてｍ大な不満を述べ１両
足にどのような異なる処置がされたのかと外科医に質問
するのが通常である。For comparison purposes, when one leg is treated with a cortisone preparation and the other leg is left untreated, the response of the fQ subjects is dramatic. It is common for patients to complain greatly about their untreated feet and ask the surgeon what different treatments were performed on both feet.
例 ２
手の掌のデュビトレン［Ｄ ｕｐｕｙｔｒｅｎ］切除手
の掌から皮下繊維組織の過剰成長を除き、露出手術組織
の谷を残す１手術組織の新表面を通常は１ｃｃ未満のコ
ルチゾン調剤１例えばセレストン懸濁体又は通常等容混
合したマルカイン及びセレストンの組合せで一回浸１．
物質は傷の新手西面にアトマイザを用いる直接噴霧か又
は注射器及び針を用いる洗浄によって適用する。コルチ
ゾン調剤は適用後食塩水で洗出されない、傷は普通に塞
ぐ、過剰のコルチゾン調剤は傷から普通に流出する０通
常の冶目が起る。EXAMPLE 2 Dupuytren Resection of the Palm of the Hand Removes excess growth of subcutaneous fibrous tissue from the palm, leaving a valley of exposed surgical tissue 1 The new surface of the surgical tissue is treated with a cortisone preparation, usually less than 1 cc, 1 e.g. One-time immersion with a suspension or a combination of marcaine and celeston, usually mixed in equal volumes.1.
The substance is applied by direct spraying with an atomizer or irrigation with a syringe and needle on the fresh west side of the wound. Cortisone preparations are not flushed out with saline after application; the wound closes normally; excess cortisone preparation drains normally from the wound; normal healing occurs.
親骨から骨移植片を取出すのは痛のある術後回復を伴う
のが通常であるが、術後傷の新手西面にコルチゾン調剤
を適用すると骨移植位置域における重大な術後不快を消
滅させる。Retrieving bone grafts from the parent bone is usually associated with a painful postoperative recovery, but application of a cortisone preparation to the new western aspect of the postoperative wound eliminates significant postoperative discomfort in the area of the bone graft site. .
これまで本発明を説明したが、当業者には本発明の範囲
内で各種の変形が可能であることが理解できよう。Although the invention has been described above, those skilled in the art will recognize that various modifications may be made within the scope of the invention.
次に本発明による術後痛を軽減又は消滅する方法をあげ
る。Next, a method of reducing or eliminating postoperative pain according to the present invention will be described.
１） 有効量のコルチゾン調剤を術後傷の新手西面に局
所適用することを包含する術後傷で引起こされる術後痛
の軽減又は消滅方法。1) A method of reducing or eliminating post-operative pain caused by a post-operative wound comprising topically applying an effective amount of a cortisone preparation to the new western aspect of the post-operative wound.
２） コルチゾン調剤をアトマイザを用いる直接噴霧に
よって術後傷の新手西面に適用する第１項記載の方法。2) The method according to paragraph 1, wherein the cortisone preparation is applied to the new west side of the postoperative wound by direct spraying using an atomizer.
３） コルチゾン調剤を注射器及び針を用いる洗浄によ
って術後傷の新手西面に適用する第１項記載の方法。3) The method of paragraph 1, wherein the cortisone preparation is applied to the new western surface of the post-operative wound by irrigation with a syringe and needle.
４） コルチゾン調剤の３ｃｃ未満を術後傷の新手西面
に局所的に適用する第１項記載の方法。4) The method of paragraph 1, wherein less than 3 cc of the cortisone preparation is applied topically to the new western aspect of the post-operative wound.
５） コルチゾン調剤がベーターメタシン アセテート
及びベーターメタシン ナトリウム フォスフェートの
懸濁体を包含する第１項記載の方法。5) The method of claim 1, wherein the cortisone formulation comprises a suspension of betamethacin acetate and betamethacin sodium phosphate.
６） 手術後の最初の数時間の間の痛の即時消滅のため
に、有効量の局所麻酔薬を術後傷の新手西面に局所適用
することをさらに包含する第１項記載の方法。6) The method of paragraph 1 further comprising locally applying an effective amount of a local anesthetic to the neo-lateral aspect of the post-operative wound for immediate relief of pain during the first few hours after surgery.
７） 局所麻酔薬とコルチゾンをほぼ同時に１１２に局
所適用する第１項記載の方法。7) The method of paragraph 1, wherein a local anesthetic and cortisone are locally applied to 112 at approximately the same time.
８） 局所麻酔薬とコルチゾンとを包含する混合物を傷
に適用する第７項記載の方法。8) The method of paragraph 7, wherein a mixture comprising a local anesthetic and cortisone is applied to the wound.
９） 該コルチゾンが局所麻酔薬を含む第１項記載の方
法。9) The method of paragraph 1, wherein the cortisone comprises a local anesthetic.
１０） 該局所麻酔薬がマルカイン、キシロカイン、
リドカイン及びノバカインのいずれかである第１項記載
の方法。10) The local anesthetic is marcaine, xylocaine,
The method according to item 1, wherein the method is either lidocaine or novacaine.
１１） 該局所麻酔薬がコルチゾンの適用前に手術面
に適用される第１項記載の方法。11) The method of paragraph 1, wherein the local anesthetic is applied to the surgical surface prior to application of cortisone.
Claims (4)
物。(1) Topical compositions including cortisone preparations and anesthetics.
及びベーターメタリンナトリウムフォスフェートの懸濁
体を包含する特許請求の範囲第１項記載の組成物。2. The composition of claim 1, wherein the cortisone preparation includes a suspension of betamethasone acetate and betamethalin sodium phosphate.
ン及びノバカインのいずれかである特許請求の範囲第１
項記載の組成物。(3) Claim 1, wherein the anesthetic is any one of marcaine, xylocaine, lidocaine, and novacaine.
Compositions as described in Section.
の範囲第１項記載の局所用組成物。(4) The topical composition according to claim 1, which is suitable for reducing or eliminating postoperative pain.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US900683 | 1986-08-27 | ||
| US7499487A | 1987-07-17 | 1987-07-17 | |
| US074994 | 1987-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63115818A true JPS63115818A (en) | 1988-05-20 |
Family
ID=22122883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62210365A Pending JPS63115818A (en) | 1986-08-27 | 1987-08-26 | Local composition for improving or extinguishing pain after operation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63115818A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
| JP2000501729A (en) * | 1995-12-12 | 2000-02-15 | オメロス メディカル システムズ，インコーポレーテッド | Vascular irrigation solution and method for controlling pain, inflammation, convulsions and restenosis |
| JP2007031454A (en) * | 1994-12-12 | 2007-02-08 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
-
1987
- 1987-08-26 JP JP62210365A patent/JPS63115818A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
| JP2007031454A (en) * | 1994-12-12 | 2007-02-08 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| JP2009024022A (en) * | 1994-12-12 | 2009-02-05 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| JP2012184274A (en) * | 1994-12-12 | 2012-09-27 | Omeros Corp | Irrigation solution and method for suppressing pain, inflammation and convulsion |
| JP2000501729A (en) * | 1995-12-12 | 2000-02-15 | オメロス メディカル システムズ，インコーポレーテッド | Vascular irrigation solution and method for controlling pain, inflammation, convulsions and restenosis |
| JP2008094855A (en) * | 1995-12-12 | 2008-04-24 | Omeros Corp | Vascular irrigation solution for and method for suppressing pain, inflammation, spasm and restenosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5272139A (en) | Amelioration or elimination of postoperative pain | |
| CA2595132C (en) | Agents for controlling biological fluids and methods of use thereof | |
| US4604384A (en) | Pharmaceutical gel composition | |
| US8535709B2 (en) | Agents for controlling biological fluids and methods of use thereof | |
| WEXLER et al. | Early treatment of burns of the dorsum of the hand by tangential excision and skin grafting | |
| JPS63115818A (en) | Local composition for improving or extinguishing pain after operation | |
| JP5796728B1 (en) | A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs. | |
| Bondoc et al. | Primary surgical management of the deeply burned hand in children | |
| CN100435807C (en) | Pharmaceutical gel composition | |
| Hill et al. | Volkmann's ischemic contracture in hemophilia | |
| CA1300505C (en) | Amelioration or elimination of postoperative pain | |
| Caprioli et al. | Surgical nail procedures | |
| JP2002507563A (en) | How to Treat Neuroma Pain | |
| Falanga et al. | Zinc chloride paste for the debridement of chronic leg ulcers | |
| DICKSON et al. | The use of sulfathiazole in the treatment of subacute and chronic osteomyelitis | |
| Shaw | Textured collagen, a hemostatic agent: A pilot study | |
| JP7450916B2 (en) | surface anesthetic | |
| Thune et al. | The analgesic effect of EMLA cream for skin biopsies | |
| AU558482B2 (en) | Pharmaceutical gel composition | |
| Tecuceanu et al. | The Particularities of Using Enzymatic Debridement Therapy in Deep Burns Treatment According to Functional Regions | |
| EP0971707A1 (en) | Compositions for the treatment of burns and external ulcers and a process for the preparation thereof | |
| Gallant | VI. Report upon the use of a mixture of castor oil and balsam of Peru as a surgical dressing | |
| Bidwell | Minor surgery | |
| FALANGA | Zinc Chloride Paste for the Debridement zyxwvutsrqponm | |
| Steinberg | A simplified technique for the surgery of ingrowing nails |